| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000370338 |
| P8608 | Fatcat ID | release_eou26lbljbbsdpu3qocskluu44 |
| P698 | PubMed publication ID | 25721705 |
| P5875 | ResearchGate publication ID | 272835258 |
| P50 | author | Emanuela Offidani | Q47702441 |
| P2093 | author name string | Giovanni A Fava | |
| Carlotta Belaise | |||
| Jenny Guidi | |||
| Alessia Gatti | |||
| P2860 | cites work | Hallucination induced by paroxetine discontinuation in patients with major depressive disorders | Q48307674 |
| Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. | Q55056668 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition) | Q56526674 | ||
| Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved | Q21129279 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Restlessness related to SSRI withdrawal | Q32111762 | ||
| The mechanisms of tolerance in antidepressant action | Q33668086 | ||
| Premature ejaculation associated with citalopram withdrawal | Q34278401 | ||
| Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. | Q34557821 | ||
| Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis | Q34995911 | ||
| Selections from current literature: benzodiazepines revisited | Q35124310 | ||
| A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal | Q36093877 | ||
| The integrative management of treatment-resistant depression: a comprehensive review and perspectives | Q38181363 | ||
| Antidepressant discontinuation reactions | Q42756523 | ||
| Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs | Q44798643 | ||
| A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder | Q44922744 | ||
| Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study | Q44993152 | ||
| Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study | Q45004223 | ||
| Electric sensations: neglected symptom of escitalopram discontinuation | Q46877872 | ||
| Delirium following abrupt discontinuation of fluoxetine. | Q46969250 | ||
| P433 | issue | 2 | |
| P921 | main subject | systematic review | Q1504425 |
| serotonin | Q167934 | ||
| SSRI discontinuation syndrome | Q175918 | ||
| P304 | page(s) | 72-81 | |
| P577 | publication date | 2015-02-21 | |
| P1433 | published in | Psychotherapy and Psychosomatics | Q15767307 |
| P1476 | title | Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review | |
| P478 | volume | 84 |
| Q36013727 | 'In my life antidepressants have been…': a qualitative analysis of users' diverse experiences with antidepressants |
| Q40746168 | A Case of Fatal Serotonin Syndrome-Like Human Rabies Caused by Tricolored Bat-Associated Rabies Virus. |
| Q99405742 | A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report |
| Q47549963 | Against the stream: Antidepressants are not antidepressants - an alternative approach to drug action and implications for the use of antidepressants |
| Q64111057 | Antidepressant Use During Acute Inpatient Care Is Associated With an Increased Risk of Psychiatric Rehospitalisation Over a 12-Month Follow-Up After Discharge |
| Q91751261 | Antidepressant Withdrawal and Rebound Phenomena |
| Q56700905 | Antidepressant discontinuation syndrome |
| Q92755149 | Antidepressant withdrawal - the tide is finally turning |
| Q89767660 | Antidepressants in inflammatory bowel disease |
| Q39396657 | Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy |
| Q90395733 | Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia |
| Q39012831 | Beliefs about the causes of depression and recovery and their impact on adherence, dosage, and successful tapering of antidepressants |
| Q91588142 | Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression |
| Q41067164 | Bilateral acute closed angle glaucoma associated with the discontinuation of escitalopram: a case report |
| Q55446033 | Bipolar disorder, comorbid anxiety disorders, gynecomastia and dental pain: case analysis with literature review. |
| Q90863593 | Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation |
| Q90400310 | Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline |
| Q37197216 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments |
| Q39296186 | Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks |
| Q92072924 | Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety, and Neuroticism Are Not Associated With Self-Reported Antidepressant Side Effects |
| Q92430456 | Complementary therapies for clinical depression: an overview of systematic reviews |
| Q67223853 | Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis |
| Q64259162 | Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants |
| Q92381532 | Delirium associated with discontinuation of sertraline in an elderly |
| Q99585315 | Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development |
| Q89964582 | Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine |
| Q92211261 | Discontinuation of antidepressant medication in primary care supported by monitoring plus mindfulness-based cognitive therapy versus monitoring alone: design and protocol of a cluster randomized controlled trial |
| Q89763945 | Discontinuing psychotropic drug treatment |
| Q47770326 | Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. |
| Q47690776 | Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults |
| Q60446818 | Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised co |
| Q92998365 | Emergent Antidepressant Discontinuation Syndrome Misdiagnosed as Delirium in the ICU |
| Q90239484 | Enhancing shared decision making about discontinuation of antidepressant medication: a concept-mapping study in primary and secondary mental health care |
| Q39009865 | Evidence-based pharmacotherapy of treatment-resistant unipolar depression |
| Q89804908 | Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database |
| Q52562530 | Imagine your mood: Study design and protocol of a randomized controlled micro-trial using app-based experience sampling methodology to explore processes of change during relapse prevention interventions for recurrent depression. |
| Q52606203 | Is There a Potential of Misuse for Venlafaxine and Bupropion? |
| Q47608840 | Long-Term and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the Netherlands |
| Q70846418 | Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review |
| Q47098457 | Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants' Efficacy and Harm |
| Q48059755 | Mindfulness-based cognitive therapy for depression |
| Q90115933 | Overprescribed Medications for US Adults: Four Major Examples |
| Q34484276 | Pharmacological treatment for generalized anxiety disorder in adults: an update |
| Q37047635 | Pharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and Tolerability |
| Q90124774 | Presentation of benefits and harms of antidepressants on websites: A cross sectional study |
| Q92993119 | Prioritization and comprehensive analysis of genes related to major depressive disorder |
| Q41025993 | Recognition and management of antidepressant discontinuation syndrome |
| Q88527763 | Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder |
| Q47599889 | Research on a 'drug-centred' approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs |
| Q93123814 | Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder |
| Q39293315 | Selective Serotonin Reuptake Inhibitors as First-Line Antidepressant Therapy for Perinatal Depression |
| Q24187263 | Selective serotonin reuptake inhibitors for fibromyalgia syndrome |
| Q90286450 | Should antidepressants be used for major depressive disorder? |
| Q58606569 | Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter! |
| Q26747097 | Switching and stopping antidepressants |
| Q92234790 | Tapering of SSRI treatment to mitigate withdrawal symptoms |
| Q64950083 | The Efficacy of a Group CBT Relapse Prevention Program for Remitted Anxiety Disorder Patients Who Discontinue Antidepressant Medication: A Randomized Controlled Trial. |
| Q39157903 | The Isoxazole Ring and Its N-Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics |
| Q91518890 | The antidepressant standoff: why it continues and how to resolve it |
| Q38764529 | The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding |
| Q31075448 | Variation and ethnic inequalities in treatment of common mental disorders before, during and after pregnancy: combined analysis of routine and research data in the Born in Bradford cohort |
| Q39306065 | Well-being therapy in depression: New insights into the role of psychological well-being in the clinical process |
| Q48247247 | What psychologists need to know about psychotropic medications |
| Q94586898 | [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic] |
| Q89017159 | [Tapering of antidementia drugs, antidepressants and antipsychotics in elderly patients : When possible, when not?] |
Search more.